Cargando…

Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension

Optimal management of systemic lupus erythematosus (SLE)‐associated pulmonary arterial hypertension (PAH) remains unclear. Our observation describes the case of a 31‐year‐old SLE patient presenting with cardiogenic shock revealing severe PAH, in which a therapeutic scheme combining immunosuppressant...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanges, Sébastien, Savale, Laurent, Lamblin, Nicolas, Rémy‐Jardin, Martine, Humbert, Marc, Sobanski, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989275/
https://www.ncbi.nlm.nih.gov/pubmed/31536678
http://dx.doi.org/10.1002/ehf2.12507
_version_ 1783492373234319360
author Sanges, Sébastien
Savale, Laurent
Lamblin, Nicolas
Rémy‐Jardin, Martine
Humbert, Marc
Sobanski, Vincent
author_facet Sanges, Sébastien
Savale, Laurent
Lamblin, Nicolas
Rémy‐Jardin, Martine
Humbert, Marc
Sobanski, Vincent
author_sort Sanges, Sébastien
collection PubMed
description Optimal management of systemic lupus erythematosus (SLE)‐associated pulmonary arterial hypertension (PAH) remains unclear. Our observation describes the case of a 31‐year‐old SLE patient presenting with cardiogenic shock revealing severe PAH, in which a therapeutic scheme combining immunosuppressants (pulse cyclophosphamide and corticosteroids) and PAH‐specific drugs (bosentan, tadalafil, and epoprostenol) led to a complete normalization of pulmonary haemodynamics and allowed a progressive weaning of PAH vasodilators. This case report supports the efficacy of immunosuppressants and use of PAH‐specific therapy as a bridge therapy in severe SLE‐PAH. Further studies on larger population are required to confirm these findings.
format Online
Article
Text
id pubmed-6989275
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69892752020-02-03 Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension Sanges, Sébastien Savale, Laurent Lamblin, Nicolas Rémy‐Jardin, Martine Humbert, Marc Sobanski, Vincent ESC Heart Fail Case Report Optimal management of systemic lupus erythematosus (SLE)‐associated pulmonary arterial hypertension (PAH) remains unclear. Our observation describes the case of a 31‐year‐old SLE patient presenting with cardiogenic shock revealing severe PAH, in which a therapeutic scheme combining immunosuppressants (pulse cyclophosphamide and corticosteroids) and PAH‐specific drugs (bosentan, tadalafil, and epoprostenol) led to a complete normalization of pulmonary haemodynamics and allowed a progressive weaning of PAH vasodilators. This case report supports the efficacy of immunosuppressants and use of PAH‐specific therapy as a bridge therapy in severe SLE‐PAH. Further studies on larger population are required to confirm these findings. John Wiley and Sons Inc. 2019-09-19 /pmc/articles/PMC6989275/ /pubmed/31536678 http://dx.doi.org/10.1002/ehf2.12507 Text en © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Sanges, Sébastien
Savale, Laurent
Lamblin, Nicolas
Rémy‐Jardin, Martine
Humbert, Marc
Sobanski, Vincent
Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title_full Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title_fullStr Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title_full_unstemmed Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title_short Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
title_sort efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989275/
https://www.ncbi.nlm.nih.gov/pubmed/31536678
http://dx.doi.org/10.1002/ehf2.12507
work_keys_str_mv AT sangessebastien efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension
AT savalelaurent efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension
AT lamblinnicolas efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension
AT remyjardinmartine efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension
AT humbertmarc efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension
AT sobanskivincent efficacyofimmunosuppressantswithbridgevasodilatortherapyinseverelupuserythematosusassociatedpulmonaryarterialhypertension